3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
2
Active not recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
22
Gastrointestinal
16
Thoracic
13
Gynecologic
7
Lymphoid
5
Head & Neck
5
Endocrine
5
CNS
5
Tumor-Agnostic
4
Sarcoma
4
Other solid neoplasm
4
Dermatologic
4
Breast
3
NET
2
Other hematologic neoplasm
1
Conditions
Neuroendocrine Tumors
2
Neoplasms
1
Carcinoma, Neuroendocrine
1
Interventions
Everolimus
19
lutetium Lu 177 dotatate
8
Octreotide
8
lanreotide
7
pasireotide
6
Temozolomide
6
Sunitinib
6
pembrolizumab
5
gallium Ga 68 dotatate
5
Positron Emission Tomography Computed Tomography
5
surufatinib
4
Sorafenib
4
Data Collection
4
Carboplatin
4
3-Iodobenzylguanidine
4
Positron-Emission Tomography
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Etoposide
3
Capecitabine
3
90Y-octreotide, DOTA-Tyr(3)-
3
pentetreotide
2
pazopanib
2
lenvatinib
2
fosbretabulin
2
fluorodopa F 18
2
cabozantinib
2
avelumab
2
arginyllysine
2
Single Photon Emission Computed Tomography Computed Tomography
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
avelumab
×
NET
×
Clear all
NCT03278379
2024-12-24
NET-002
Sunnybrook Health Sciences Centre
Phase 2
Completed
17 enrolled
NCT03352934
2022-02-25
AveNEC
Johannes Gutenberg University Mainz
Phase 2
Completed
60 enrolled